DAFNA Capital Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

DAFNA Capital Management’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-524,664	Closed	-$1.21M	–	97
2020 Q2	$1.21M	Sell	524,664 -17,900	-3%	-$41.2K	0.35%	52
2020 Q1	$933K	Hold	542,564	–	–	0.39%	51
2019 Q4	$1.12M	Hold	542,564	–	–	0.39%	57
2019 Q3	$1.57M	Sell	542,564 -191,858	-26%	-$655K	0.59%	43
2019 Q2	$2.88M	Buy	734,422 +485,715	+195%	+$2.53M	1.08%	27
2019 Q1	$1.17M	Buy	+248,707	New	+$1.23M	0.51%	47

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DAFNA Capital Management's GNCA Position: Q3 2020 in Review

DAFNA Capital Management sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2020, closing a stake of 524,664 shares — an estimated $1.21M sold.

DAFNA Capital Management first reported a position in GNCA in Q1 2019 and held it in 6 quarters. The position peaked at $2.88M in Q2 2019. 39 funds tracked by Wall St. Rank hold GNCA as of Q3 2020.

DAFNA Capital Management reported no remaining Genocea Biosciences, Inc. position as of Q3 2020 after selling out during the quarter.
DAFNA Capital Management sold 524,664 Genocea Biosciences, Inc. shares in Q3 2020, an estimated $1.21M.
DAFNA Capital Management first reported a position in Genocea Biosciences, Inc. in Q1 2019 and held it in 6 quarters.
DAFNA Capital Management's Genocea Biosciences, Inc. position peaked at $2.88M in Q2 2019.
39 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2020.

Based on DAFNA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.